GlassScriptPhysician profile
Marc S Feldstein
NPI 1730145566
$7,530.92
in general payments reported to CMS, 2019-2025
33 companies · $470 in 2025
The $470 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,012 · 2020: $761 · 2021: $1,062 · 2022: $1,198 · 2023: $1,196 · 2024: $832 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,227.26 | 2019-2025 | |
| Gynesonics, INC. | $948.42 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Asensus Surgical, INC. | $837.98 | 2019 | |
| Novo Nordisk INC | $271.81 | 2024-2025 | Wegovy |
| Allergan, INC. | $266.04 | 2019-2020 | |
| Myriad Women'S Health, INC. | $253.74 | 2023 | Myrisk |
| Therapeuticsmd, INC. | $235.67 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $234.55 | 2022-2025 | |
| Pfizer INC. | $205.63 | 2019-2024 | |
| Coopersurgical, INC. | $196.01 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Lupin INC. | $176.69 | 2019 | |
| Myovant Sciences INC. | $171.45 | 2022 | |
| Roche Diagnostics Corporation | $162.74 | 2019-2020 | |
| Exeltis, USA INC. | $160.37 | 2019-2024 | Slynd |
| Hologic Sales and Service, LLC | $140.41 | 2019-2025 | Aptima, Novasure, Omni Hysteroscope |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $127.53 | 2021-2024 | Twirla |
| Mylan Pharmaceuticals INC. | $115.06 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $102.76 | 2020-2021 | |
| Aspira Women'S Health INC | $98.86 | 2021-2025 | Ova1 |
| Avion Pharmaceuticals | $96.21 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $92.37 | 2019-2023 | Vaxneuvance, Vaqta, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $79.29 | 2019-2023 | |
| Astellas Pharma US INC | $75.16 | 2024-2025 | Veozah |
| Vertex Pharmaceuticals Incorporated | $42.06 | 2024-2025 | |
| Dysis Medical, INC. | $36.05 | 2020-2022 | |
| Millicent US INC | $31.02 | 2024 | Femring, Intrarosa |
| Exact Sciences Corporation | $28.12 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $26.05 | 2025 | Zepbound |
| Medtronic, INC. | $22.66 | 2023 | Truclear |
| Sumitomo Pharma America, INC. | $20.44 | 2024 | Myfembree |
| Organon LLC | $20.41 | 2022 | |
| Boston Scientific Corporation | $14.54 | 2019 | |
| Becton, Dickinson and Company | $13.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Feldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.